Group tries to halt FDA regulation of lab-developed tests; Symbios smacked with Class I recall label;

 @FierceMedDev: Life Tech buys Korean distributor as Thermo waits. News | Follow @FierceMedDev

 @DamianFierce: Venture-backed Natera is expanding its prenatal test as it contends with $SQNM, $ILMN and others. Article | Follow @DamianFierce

 @MarkHFierce: Just met in Berlin with Christian Pangratz, CBO of Activaero, which has a promising drug-device liquid inhalation treatment for asthma. | Follow @MarkHFierce

 @MichaelGFierce: Chime in on the nano-gold discussion at the FierceBiotech LinkedIn page: Discussion | Follow @MichaelGFierce

> The American Clinical Laboratory Association is trying to stop the FDA's push to regulate laboratory-developed tests as medical devices. Story

> The FDA slapped a Class I recall status--its most serious label--on Symbios' GoPump Rapid Recovery System, a disposable pain-management device that includes a small balloon. Notice

> Amarantus Bioscience Holdings sealed a deal with BD Biosciences allowing BD to analyze samples for Amarantus' LymPro test for Alzheimer's disease. Item

> AngioScore won FDA approval of a PMA supplement labeling change, allowing the inclusion of a clinical trial results summary on its AngioSculpt PTCA Scoring Balloon angioplasty catheter's instructions for use. Item

> VentureHealth is rolling out an online equity crowdfunding platform for life sciences companies. Story

> Abyrx won FDA clearance for its new absorbable hemostatic bone putty, which comes ready-to-use. Item

> NASA launched a new funding program designed to spur healthcare/med tech entrepreneurs to develop healthcare products useable in space and on earth. Story

> Spectral MD is touting a new FDA 510(k) clearance for its DeepView medical imaging system, for studies of blood flow in microcirculation. Item

Biotech News

 @FierceBiotech: Report: Genomics industry contributed $1 trillion to U.S. economy in last 25 years. Article | Follow @FierceBiotech

 @JohnCFierce: Royalty Pharma scrambles to salvage vote on hostile Elan takeover. Story | Follow @JohnCFierce

 @RyanMFierce: GSK has halted a study of an MS compound linked to data fraud in China. The plot thickens. More | Follow @RyanMFierce

 @EmilyMFierce: SCOTUS decision on Myriad case: Natural isolated DNA is not patentable. Synthetic DNA is patentable because it doesn't occur naturally. | Follow @EmilyMFierce

> Japanese biotech Prism snags $15M C round for cancer, fibrosis studies. News

> Lilly's oral rheumatoid arthritis blockbuster contender champions 1-year study. News

> Glaxo's dismissed China R&D chief fires back. Article

Pharma News

 @FiercePharma: Catalent kicks off $35M expansion in U.S. More | Follow @FiercePharma

 @EricPFierce: Novo suggests overzealous reading of risks of Type 2 diabetes drugs that include Victoza, Januvia. Article | Follow @EricPFierce

 @CarlyHFierce: Insider trading charges from Sanofi/Chattem deal continue to pile up. Brothers allegedly scored a $50k profit. Report | Follow @CarlyHFierce

> GSK probes sales tactics in China days after firing R&D chief there. More

> AARP fears Pfizer tactics to defend Lipitor could become model. Story

Pharma Manufacturing News

> Zydus recalls warfarin after oversized tablets discovered. Item

> FedEx vows not to settle with feds on online pharmacy shipments. Story

> FDA warning letter nails 2 Baxter plants for repeat violations. Article

> FDA comes down on another Indian drugmaker. Report

Vaccines News

> Latin American cancer vax races Big Pharma rivals. More

> FDA clears Sanofi to compete for 4-in-1 flu vaccine market. Report

> FDA setback sends Dynavax shares tumbling again. Article

> Oral vaccine aims to end dreaded Delhi belly. Story

Suggested Articles

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.

The FDA has given Grail a green light to conduct the interventional study, and it has begun enrolling participants through the company’s R&D partners.

Coronavirus may not require a front-line battle yet in certain places, but it’s still taxing public health officials preparing for a potential crisis.